This is a two-part protocol. This protocol is for Part A, the specific aims of which are to:
1. Determine the optimal dose (21 mg or 14 mg) and duration (24 hours or 16 hours) of nicotine replacement using the nicotine transdermal delivery device for African-American pregnant women who smoke, and
2. Determine the implications of the nicotine replacement studies for treatment with the nicotine replacement patch of African-American women who smoke during pregnancy.
Additional aims are to:
1\. Collect DNA for exploratory analyses regarding genetic causes of differences in metabolism of nicotine and cotinine.
Latina/Hispanic women will not be included in this study because a) few smoke, and b) few are seen in the clinical sites from which participants will be recruited.
